Andrew Felis, DO
Nephrology · Mobile, ALNPI 1407275068
Payments from drug & device makers
What this record shows
This record is dominated by grants: $25,061 of the $34,637 with a category attached, or 72.4%. Sanofi accounts for 72.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $25,398 and has fallen 97.7% since, to $576 in 2025. Among nephrology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $189.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$25K
- Amgen$7K
- AstraZeneca$350
- Calliditas Therapeutics US Inc.$259
- Otsuka America Pharmaceutical, Inc.$252
- Bayer$228
- plus $1K from 12 others
What the payments were for
- Speaking & faculty fees$3,80011%
- Grants$25,06172%
- Travel & lodging$1,7855%
- Food & beverage$3,72611%
- Education$2651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $25,061 |
| Amgen(2 entities) | 82 | $7,296 |
| AstraZeneca(2 entities) | 15 | $350 |
| Calliditas Therapeutics US Inc. | 12 | $259 |
| Otsuka America Pharmaceutical, Inc. | 14 | $252 |
| Bayer | 11 | $228 |
| Travere Therapeutics, Inc. | 9 | $217 |
| Fresenius USA Marketing, Inc. | 6 | $206 |
| Nxstage Medical, Inc. | 2 | $180 |
| Akebia Therapeutics Inc | 6 | $110 |
| Daiichi Sankyo Inc. | 5 | $91 |
| Novartis | 4 | $90 |
| Mallinckrodt Hospital Products Inc. | 3 | $75 |
| GSK | 4 | $68 |
| Vifor Pharma, Inc. | 4 | $61 |
| Aurinia Pharma U.S., Inc. | 3 | $56 |
| Lilly USA, LLC | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$25,061
- KRYSTEXXA$5,585
- Velphoro$125
How this compares
$34,637 in reported general payments places this provider in the 90th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 119 | $88,723 |
| JardianceEmpagliflozin | 67 | $55,609 |
| AuryxiaFerric Citrate | 29 | $45,655 |
| VelphoroSucroferric Oxyhydroxide | 24 | $36,936 |
| KerendiaFinerenone | 28 | $22,936 |
| Sevelamer Carbonate | 37 | $18,165 |
| EntrestoSacubitril/Valsartan | 16 | $15,074 |
| Torsemide | 95 | $2,580 |
| Colchicine | 55 | $1,538 |
| Chlorthalidone | 137 | $1,306 |
| Furosemide | 249 | $1,167 |
| Allopurinol | 128 | $1,049 |
| Calcitriol | 55 | $863 |
| Hydralazine Hcl | 52 | $859 |
| Losartan Potassium | 92 | $726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $350 | $88,723119 claims |
| Akebia Therapeutics IncAuryxia | $110 | $45,65529 claims |
| Fresenius USA Marketing, Inc.Velphoro | $206 | $36,93624 claims |
| BayerKerendia | $228 | $22,93628 claims |
| NovartisEntresto | $90 | $15,07416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 164 nephrology providers in Alabama.
Other nephrology in Mobile
- Michael KleinmannMobile$50K
- Douglas AmareMobile$10K
- Roy CulpepperMobile$5K
- Purnima TripathyMobile$5K
- Christopher MireMobile$5K
- Richard MeadorMobile$4K
- John NipperMobile$4K
- Errol CrookMobile$4K
- Stephen WilberMobile$4K
- Michael QuadriniHuntsville$323K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.